Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A very rare, slow-growing, clinically serious endocrine tumor that generally develops in mid-adulthood. PRTC presents as a palpable painless mass in the neck and causes severe hypercalcemia and related symptoms, non-specific gastrointestinal manifestations, as well as renal and bone complications related to primary hyperparathyroidism (nephrolithiasis, impaired renal function, osteoporosis, bone pain, and pathologic fractures, etc.). Some PRTCs are however non-functioning tumors.
Features include always present findings: Parathyroid carcinoma and Primary hyperparathyroidism; and very common findings: Hypophosphatemia, Hypercalciuria, Elevated circulating parathyroid hormone level, and Abnormal parathyroid morphology. 37 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 6 | Nephrocalcinosis, Nephrolithiasis, Reduced kidney function (renal insufficiency) |
Digestive system | 6 | Difficulty swallowing (dysphagia), Pancreatitis, Nausea and vomiting |
Brain and nerves | 3 | Difficulty swallowing (dysphagia), Fatigue, Headache |
Bones and joints | 2 | Weak and brittle bones (osteoporosis), Bone pain |
Lab test results | 1 | Elevated circulating parathyroid hormone level |
Growth and development | 1 | Weight loss |
Muscles | 1 | Muscle weakness |
Head and neck | 1 | Mandibular pain |
Hormones | 1 | Thyroid carcinoma |
The spectrum of CDC73-related disorders includes the following overlapping phenotypes:
Hyperparathyroidism-jaw tumor (HPT-JT) syndrome
Parathyroid carcinoma
Familial isolated hyperparathyroidism (FIHP)
Primary hyperparathyroidism. Individuals with primary hyperparathyroidism may be asymptomatic or may present with nephrolithiasis, reduced bone mass, fracture, fatigue, muscle weakness, bone or joint pain, and/or constipation. Primary hyperparathyroidism occurs in up to 95% of individuals with HPT-JT syndrome. The onset is typically in late adolescence or early adulthood and is often the first feature of HPT-JT syndrome . The youngest reported individual with hypercalcemia was age seven years .
Source: GeneReviews — "CDC73-Related Disorders"
CDC73 encodes cell division cycle 73 (531 aa). Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Highest expression in Artery Tibial (32.6 TPM) and Cells Cultured fibroblasts (30.0 TPM).
Parathyroid gland carcinoma is associated with mutations in the CDC73 gene on chromosome 1.
The CDC73 protein participates in GLI proteins bind CDC73 and Beta-catenin recruits CDC73 and LEO1 pathways.
CDC73 is classified as a druggable target (Clinically Actionable and Enzyme categories) with score 0.0.
Although no genotype-phenotype correlations for CDC73 pathogenic variants have been formally established to date, it has been suggested that pathogenic missense variants are more likely to be associated with the FIHP phenotype; pathogenic variants that cause gross disruption of the protein product are more likely to be associated with the HPT-JT phenotype. However, some variants (e.g., , ) have been reported in association with more than one CDC73-associated phenotype . Families with FIHP appear to have a higher ratio of missense to frameshift/nonsense variants than families with HPT-JT syndrome (4/7 vs 3/38, respectively) [, , , , , , , , , ]. A study of 419 individuals with a CDC73 germline pathogenic variant suggested several genotype-phenotype correlations .
Source: GeneReviews — "CDC73-Related Disorders"
While the penetrance in HPT-JT syndrome is estimated at 80%-90%, lower penetrance in females has been reported in two families and was closer to 70% in two different studies . The overall age-related penetrance in a Dutch population was estimated to be 11% at age 25 years, 65% at age 50 years, and 83% at age 70 years . In a series of 61 individuals, 93% showed some manifestation of HPT-JT syndrome by age 40 years .
Source: GeneReviews — "CDC73-Related Disorders"
CDC73-related disorders should be suspected in individuals with any of the following clinical, family history, laboratory, radiographic, and/or histopathology features.
Clinical features
Primary hyperparathyroidism and ossifying fibroma(s) of the jaw
Primary hyperparathyroidism with age of onset 45 years and cystic, atypical, and/or malignant parathyroid histology
Childhood- or adolescent-onset primary hyperparathyroidism
Childhood-onset ossifying fibroma(s) of the maxilla or mandible. Note: The frequency of CDC73 pathogenic variants in individuals with apparently sporadic ossifying fibromas of the jaw appears low ; however, this has not been extensively studied .
Source: GeneReviews — "CDC73-Related Disorders"
The following disorders should be considered in the differential diagnosis of CDC73-related disorders. Primary Hyperparathyroidism/ Familial Isolated Hyperparathyroidism Sporadic primary hyperparathyroidism. Primary hyperparathyroidism has a prevalence of one to three in 1,000 in the general population, with a female-to-male ratio of approximately 2.5:1 . Sporadic primary hyperparathyroidism is typically caused by a single parathyroid adenoma, with peak age of onset in the sixth decade of life. Sporadic atypical parathyroid adenomas do not tend to show loss of CDC73 staining . Hereditary primary hyperparathyroidism/ familial isolated hyperparathyroidism. See . Table 2. Genes of Interest in the Differential Diagnosis of Primary Hyperparathyroidism/ Familial Isolated Hyperparathyroidism
Gene | Disorder | MOI | Clinical Characteristics |
|---|---|---|---|
GNA11 | Familial hypocalciuric hypercalcemia (FHH) (OMIM PS145980) |
Genetic testing for CDC73 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for parathyroid gland carcinoma has been reported in the published literature.
No approved treatments are currently available for parathyroid gland carcinoma. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual identified to have a pathogenic variant in CDC73, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
CDC73-Related Disorders: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| • Measurement of concomitant serum calcium iPTH
Serum 25-hydroxyvitamin D to evaluate for coexisting vitamin D deficiency as a cause of iPTH or unexpectedly "normal" calcium concentrations
| Beginning by age 10 yrs
24-hour urine calcium-to-creatinine clearance ratio | In persons w/hypercalcemia
DXA scan to assess bone density of lumbar spine, hips, distal radius | As indicated
| Panoramic jaw x-ray w/neck shielding | Beginning at diagnosis
| Renal US is preferred; CT /or MRI as clinically indicated
| • Pelvic exam as part of routine gynecologic care
Pelvic US is preferred; CT /or MRI as clinically indicated
| Beginning in women at reproductive age
| By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of CDC73-related disorders to facilitate medical personal decision making
DXA = dual-energy x-ray absorptiometry; iPTH = intact parathyroid hormone; MOI = mode of inheritance; US = ultrasound
1. Medical geneticist, certified genetic counselor, certified advanced genetic nurse
Source: GeneReviews — "CDC73-Related Disorders"
The following should be avoided:
Dehydration
Radiation exposure to the neck
Biopsy of extrathyroidal tissue in the neck, which increases the risk of seeding of parathyroid tissue
Source: GeneReviews — "CDC73-Related Disorders"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "CDC73-Related Disorders"
9 trials found
There are currently no well-established, evidence-based surveillance guidelines for individuals with a CDC73-related disorder. Based on an extensive literature review and to monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended.
Table 5.
CDC73-Related Disorders: Recommended Surveillance
System/Concern | Evaluation | Frequency
Primary hyperparathyroidism/
| • Measurement of concomitant serum calcium iPTH
Serum 25-hydroxyvitamin D to evaluate for coexisting vitamin D deficiency as a cause of iPTH or unexpectedly "normal" calcium concentrations
| Annually beginning by age 10 yrs
Consider neck US exam for detection of nonfunctioning parathyroid carcinoma. | Periodically as indicated based on serum calcium iPTH levels
Evaluate via localization studies1 for new primary parathyroid tumor or recurrence/progression of malignant disease. | In those w/history of parathyroid carcinoma, who develop a rise in calcium levels
| • Regular dental visits
Note: Dental providers should be notified of presence of a CDC73-related disorder need for monitoring for osseous fibromas of maxilla mandible.
| Every 6 mos
Panoramic jaw x-ray w/neck shielding | At least every 5 yrs beginning at diagnosis
| • Renal US exam to assess for kidney lesions
CT or MRI as clinically indicated
Serum creatinine concentrations in those w/kidney cysts | Annually
| • Gynecol...
Source: GeneReviews — "CDC73-Related Disorders"
Phenotype severity distribution: 2 always present features, 4 very common features, 12 common features.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
9 clinical trials registered, 7 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and procedural interventions. Pipeline includes 3 PHASE2, 2 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07444723](https://clinicaltrials.gov/study/NCT07444723) | Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors | PHASE2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | RECRUITING |
[NCT06852144](https://clinicaltrials.gov/study/NCT06852144) | PET-TC in Thyroid Evaluation | — | IRCCS Azienda Ospedaliero-Universitaria di Bologna | ENROLLING_BY_INVITATION |
[NCT04969926](https://clinicaltrials.gov/study/NCT04969926) | Natural History Study of Parathyroid Disorders | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | RECRUITING |
[NCT07475780](https://clinicaltrials.gov/study/NCT07475780) | Radiofrequency Ablation For Recurrent Parathyroid Carcinoma | NA | M.D. Anderson Cancer Center | RECRUITING |
[NCT02834013](https://clinicaltrials.gov/study/NCT02834013) | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | PHASE2 | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
151 publications have been identified in PubMed for parathyroid gland carcinoma. Kisho has analyzed 50 by research type. Research spans Review / Meta-Analysis (56%), Case Report / Case Series (12%), and Basic Science / Preclinical (10%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 28 | 56% |
Patient case studies | 6 | 12% |
Laboratory research | 5 | 10% |
Disease patterns and progression | 5 | 10% |
Testing and diagnosis research | 3 | 6% |
Clinical study results | 3 |
Azeez TA (2026). [PMID: 41927017](https://pubmed.ncbi.nlm.nih.gov/41927017/). *Horm Metab Res*. [Review / Meta-Analysis]
Li P (2026). [PMID: 40505957](https://pubmed.ncbi.nlm.nih.gov/40505957/). *J Adv Res*. [Basic Science / Preclinical]
Erickson LA (2026). [PMID: 41490755](https://pubmed.ncbi.nlm.nih.gov/41490755/). *Hum Pathol*. [Review / Meta-Analysis]
Matsuo T (2026). [PMID: 41284057](https://pubmed.ncbi.nlm.nih.gov/41284057/). *Surg Today*. [Diagnostic / Biomarker]
Juhlin CC (2026). [PMID: 41238829](https://pubmed.ncbi.nlm.nih.gov/41238829/). *Virchows Arch*. [Review / Meta-Analysis]
Serani F (2026). [PMID: 41533239](https://pubmed.ncbi.nlm.nih.gov/41533239/). *EJNMMI Res*. [Case Report / Case Series]
Altintop SE (2025). [PMID: 40263174](https://pubmed.ncbi.nlm.nih.gov/40263174/). *Endocrine*. [Diagnostic / Biomarker]
Khot R (2025). [PMID: 40440190](https://pubmed.ncbi.nlm.nih.gov/40440190/). *Radiographics*. [Review / Meta-Analysis]
Marini F (2025). [PMID: 39939267](https://pubmed.ncbi.nlm.nih.gov/39939267/). *Best Pract Res Clin Endocrinol Metab*. [Review / Meta-Analysis]
Viswanath A (2025). [PMID: 39743453](https://pubmed.ncbi.nlm.nih.gov/39743453/). *Best Pract Res Clin Endocrinol Metab*. [Review / Meta-Analysis]
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 6:02 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AD
CASR-related FHH is a benign condition characterized by hypercalcemia, low urinary calcium excretion (assessed via a calcium-to-creatinine clearance ratio), normal to minimally PTH, frequent hypermagnesemia. Biochemical findings in FHH can overlap w/those of primary hyperparathyroidism. |
CASR | Familial isolated hyperparathyroidism (FIHP)1 | AD | Heterozygous CASR pathogenic variants have been reported in 14%-18% of persons w/FIHP.1 |
Neonatal severe primary hyperparathyroidism (OMIM 239200) | AR(AD) | Rare condition assoc w/severe neonatal or infantile hypercalcemia hyperparathyroidism that may lead to death if untreated. Diagnosis is typically w/in 1st mo of life but may range from birth to ~3 mos.2 | — |
CDKN1B | Multiple endocrine neoplasia type 4 (MEN4) | AD | Phenotype overlaps w/MEN1; however, less is known about penetrance of MEN4 assoc lifetime risk for endocrine tumors.; Primary hyperparathyroidism tends to occur at a later age in MEN4 than in MEN1. |
GCM2 | FIHP type 4 (OMIM 617343) | AD | Early data suggest that persons w/GCM2-related primary hyperparathyroidism are more likely to have aggressive disease, incl lower rate of biochemical cure incidence of parathyroid carcinoma.; Persons in these kindreds do not appear to be at risk for other endocrine tumors. |
MAX | Multiple endocrine neoplasia type 5 (MEN5)3 | AD | Primarily heredita... |
Source: GeneReviews — "CDC73-Related Disorders"
AI-curated news mentioning parathyroid gland carcinoma
Updated Sep 3, 2026
A 20-year case study highlights parathyroid carcinoma located in a nonorthotopic supraclavicular area, providing insights into its long-term progression. This research contributes to the understanding of rare tumor presentations and their management.
A new study discusses the management strategies for aggressive forms of primary hyperparathyroidism, specifically focusing on parathyroid carcinoma and atypical parathyroid tumors. The findings may influence treatment protocols for these rare conditions.
Recent research utilizes single-cell and spatial transcriptomics to identify a progenitor subpopulation and fibroinflammatory niche in parathyroid carcinoma. This study enhances understanding of the tumor microenvironment, potentially guiding future therapeutic strategies.